ACRS News and Press, Aclaris Therapeutics Inc. From 11/29/22

WAYNE, Pa. and SHANGHAI, China, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, and Pediatrix Therapeutics, Inc. (Pediatrix), a pediatrics-fo...

WAYNE, Pa., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that the company will participate in two November healthcare inve...

- Completed Enrollment in Phase 2a Trial of Zunsemetinib in Hidradenitis Suppurativa; Topline Data Expected in Mid-first Half of 2023 - Announced Patent License Agreement with Lilly for the Treatment of Alopecia Areata with Proceeds of $17.6 million - Successfu...

BTIG has initiated Aclaris Therapeutics ( NASDAQ: ACRS ) with a buy saying that the company's oral MK2 inhibitor, zunsemetinib, in phase 2 for several inflammatory conditions, could be attractive given black box warnings associated with JAK inhibitors. The firm has a $32 p...

WAYNE, Pa., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that it has appointed Robert A. Doody Jr. as Vice President, Inv...

WAYNE, Pa., Aug. 30, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that Dr. Neal Walker, CEO of Aclaris, will virtually present a co...

Aclaris Therapeutics ( NASDAQ: ACRS ) signed a non-exclusive patent license agreement with Eli Lilly ( LLY ) for baricitinib to treat alopecia areata, a hair loss disorder. Under the agreement, Aclaris granted Lilly non-exclusive rights under certain pate...

WAYNE, Pa., Aug. 25, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced a non-exclusive patent license agreement with Eli Lilly and Compa...

Aclaris Therapeutics press release ( NASDAQ: ACRS ): Q2 GAAP EPS of -$0.31 beats by $0.05 . Revenue of $1.53M (-15.9% Y/Y) misses by $0.08M . For further details see: Aclaris Therapeutics GAAP EPS of -$0.31 beats by $0.05, revenue of $1.53M misses by $0.0...

WAYNE, Pa., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced its financial results for the second quarter of 2022 and provided...